What does the evidence say about Pomegranate Blood Pressure Meta-Analysis?

The current Migaku evidence database contains 2 reusable source documents for Pomegranate Blood Pressure Meta-Analysis. This answer focuses on benefits, uncertainty, and practical interpretation. - Pomegranates are fruits with a high phenol content that have an antihypertensive effect. [Betanzos-Cabrera G (2026); evidence level 2] - Objective This randomized postprandial pilot study evaluated microencapsulated pomegranate juice (MPJ) as a natural antihypertensive agent in patients with mild hypertension. [Betanzos-Cabrera G (2026); evidence level 2] - Hormonal changes associated with this stage of life contribute to a higher CVD risk, driven by factors such as visceral obesity, atherogenic dyslipidemia, vascular dysfunction, and high blood pressure (BP). [Almoraie Manal M (2026); evidence level 2] - However, a direct association between menopause and increased risk of CVD events has only been confirmed in cases of early (premature) menopause [,]. [Almoraie Manal M (2026); evidence level 2] - Non-fasting triacylglycerol (TAG) concentrations are an independent, modifiable CVD risk factor [,], and considered more discriminatory of risk than fasting concentrations in women [,,]. [Almoraie Manal M (2026); evidence level 2] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.